Patents by Inventor Russell Drew Cink

Russell Drew Cink has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SALTS OF FENOFIBRIC ACID AND PHARMACEUTICAL FORMULATIONS THEREOF
    Publication number: 20140187561
    Abstract: In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.
    Type: Application
    Filed: July 29, 2013
    Publication date: July 3, 2014
    Inventors: Russell Drew Cink, Joseph B. Paterson, Jr., Yi Gao, Geoff G.Z. Zhang, Michelle A. Long, John B. Morris, Joerg Rosenberg
  • SALTS OF FENOFIBRIC ACID AND PHARMACEUTICAL FORMULATIONS THEREOF
    Publication number: 20130018101
    Abstract: In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 17, 2013
    Inventors: Russell Drew Cink, Joseph B. Paterson, JR., Yi Gao, Geoff G. Z. Zhang, Michelle A. Long, John B. Morris, Joerg Rosenberg
  • Crystalline form of the compound A-348441
    Patent number: 8124129
    Abstract: There is provided a hemihydrate of (3?,5?,7?,12?)-7,12-dihydroxy-3-{2-[{4-[17?-hydroxy-3-oxo-17?-prop-1-ynylestra-4,9-dien-11?-yl]phenyl}(methyl)amino]ethoxy}cholan-24-oic acid in a crystalline form which is characterised by an X-ray diffraction pattern having major peaks at 2?=6.58±0.2, 8.54+0.2, 12.28±0.2, and 19.68±0.2. This crystalline material is useful in the treatment of conditions associated with an excess of hepatic glucocorticoid response.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: February 28, 2012
    Assignee: Karo Bio AB
    Inventors: Russell Drew Cink, Daozhong Zou, Marvin Robert Leanna, Pascal H. Toma, Michelle Andrée Long
  • Crystalline Form of the Compound A-348441
    Publication number: 20090176754
    Abstract: There is provided a hemihydrate of (3?, 5?, 7?, 12?)-7,12-dihydroxy-3-{2-[{4-[17?-hydroxy-3-oxo-17?-prop-1-ynylestra-4,9-dien-11?-yl]phenyl}(methyl)amino]ethoxy}cholan-24-oic acid in a crystalline form which is characterised by an X-ray diffraction pattern having major peaks at 2?=6.58±0.2, 8.54+0.2, 12.28±0.2, and 19.68±0.2. This crystalline material is useful in the treatment of conditions associated with an excess of hepatic glucocorticoid response.
    Type: Application
    Filed: July 12, 2006
    Publication date: July 9, 2009
    Inventors: Russell Drew Cink, Daozhong Zou, Marvin Robert Leanna, Pascal H. Toma, Michelle Andree Long
  • Glucocorticoid receptor ligands for the treatment of metabolic disorders
    Patent number: 7521439
    Abstract: This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in the regulation of metabolism, especially lowering serum glucose levels, insulin levels, or lipid levels, and/or decreasing body weight.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: April 21, 2009
    Assignee: Karo Bio AB
    Inventors: Richard D. Bishop, Russell Drew Cink, Bradley D. Gates, Lars T. Hagberg, Peer B. Jacobsen, Philip R. Kym, Chunqiu Lai, Marvin Robert Leanna, James T. Link, Steven J. Richards, Noah Tu, Tom W. von Geldern
  • Salts of fenofibric acid and pharmaceutical formulations thereof
    Patent number: 7259186
    Abstract: In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: August 21, 2007
    Assignee: Abbott Laboratories
    Inventors: Russell Drew Cink, Joseph B. Paterson, Jr., Yi Gao, Geoff G. Z. Zhang, Michelle A. Long, John B. Morris, Joerg Rosenberg
  • Glucocorticoid receptor ligands for the treatment of metabolic disorders
    Patent number: 7141559
    Abstract: This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in the regulation of metabolism, especially lowering serum glucose levels, insulin levels, or lipid levels, and/or decreasing body weight.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: November 28, 2006
    Assignee: Karo Bio AB
    Inventors: Richard D. Bishop, Russell Drew Cink, Bradley D. Gates, Lars T. Hagberg, Peer B. Jacobsen, Philip R. Kym, Chunqiu Lai, Marvin Robert Leanna, James T. Link, Steven J. Richards, Noah Tu, Tom W. von Geldern
  • Novel glucocorticoid receptor ligands for the treatment of metabolic disorders
    Publication number: 20040235810
    Abstract: This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in the regulation of metabolism, especially lowering serum glucose levels, insulin levels, or lipid levels, and/or decreasing body weight.
    Type: Application
    Filed: June 12, 2003
    Publication date: November 25, 2004
    Inventors: Richard D. Bishop, Russell Drew Cink, Bradley D. Gates, Lars T. Hagberg, Peer B. Jacobson, Philip R. Kym, Chunqui Lai, Marvin Robert Leanna, James T. Link, Steven J. Richards, Noah Tu, Tom W. von Geldern
  • Phorboxazole derivatives for treating cancer
    Patent number: 6797721
    Abstract: Synthetic Phorboxazole A and derivatives thereof for the treatment of cancer, including inhibition of cancer cell growth, induction of apoptosis, and inhibition of metastises.
    Type: Grant
    Filed: May 14, 2002
    Date of Patent: September 28, 2004
    Assignees: Parker Hughes Institute, Regents of the University of Minnesota
    Inventors: Fatih M. Uckun, Rama K. Narla, Craig Forsyth, Chi Sing Lee, Feryan Ahmed, Russell Drew Cink